↓ Skip to main content

Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM

Overview of attention for article published in Journal of Neuro-Oncology, December 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
3 X users
patent
1 patent

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
79 Mendeley
Title
Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM
Published in
Journal of Neuro-Oncology, December 2014
DOI 10.1007/s11060-014-1675-z
Pubmed ID
Authors

Pankaj Pathak, Prerana Jha, Suvendu Purkait, Vikas Sharma, Vaishali Suri, Mehar C. Sharma, Mohammed Faruq, Ashish Suri, Chitra Sarkar

Abstract

Mutations in H3.3-ATRX-DAXX chromatin remodeling pathway have been reported in pediatric GBMs. H3.3 (H3F3A) mutations may affect transcriptional regulation by altered global histone-methylation. Therefore, we analyzed yet partly understood global histone code (H3K-4/9/27/36) trimethylation pattern in H3F3A-ATRX mutants and wild-type. H3F3A, HIST1H3B, IDH1, ATRX, DAXX and Tp53 mutations were identified by sequencing/immunohistochemistry in 27 pediatric GBMs. Global histone-methylation H3K-4/9/27/36me3 and Polycomb-protein EZH2 expression were evaluated by immunohistochemistry. H3F3A-ATRX mutation was observed in 66.7 % (18/27) of pediatric GBMs. K27M and G34R-H3F3A mutations were found in 37 % (10/27) and 14.8 % (4/27) patients respectively. G34V-H3F3A, HIST1H3B and IDH1 mutations were absent. Notably, commonest global histone-methylation mark lost was H3K27me3 (17/25, 68 %) followed by H3K4me3 (45.5 %, 10/22) and H3K9me3 (18.2 %, 4/22). Global H3K36me3 showed no loss. Most significant observation was loss of one or more histone-trimethylation mark in 80 % (20/25) pediatric GBMs. Notably, simultaneous loss of H3K27me3 and H3K4me3 were present in 7/22 (31.8 %) of pediatric GBMs. Low expression of EZH2 was found in 12/24 (50 %) of cases. However no significant correlation of loss of histone-marks or EZH2 expression with H3F3A-ATRX mutants (loss of at least one histone-marks in 87.5 % (14/16) cases) versus wild-types (loss of at least one histone-marks in 75 % (6/8) cases) was seen. The present study highlights for the first time combinatorial loss of one or more histone-trimethylation marks associated with majority of pediatric GBMs and the finding suggests significant role of histone-code in the molecular biology that underlies pediatric GBMs. Hence therapies for patients with particular combinations of histone modifications present opportunity to design innovative patient-tailored treatment protocols.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 3%
Czechia 1 1%
Unknown 76 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 19%
Student > Ph. D. Student 14 18%
Student > Master 9 11%
Student > Doctoral Student 8 10%
Student > Postgraduate 6 8%
Other 15 19%
Unknown 12 15%
Readers by discipline Count As %
Medicine and Dentistry 22 28%
Biochemistry, Genetics and Molecular Biology 19 24%
Agricultural and Biological Sciences 14 18%
Neuroscience 3 4%
Immunology and Microbiology 2 3%
Other 2 3%
Unknown 17 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2018.
All research outputs
#6,093,723
of 22,772,779 outputs
Outputs from Journal of Neuro-Oncology
#716
of 2,964 outputs
Outputs of similar age
#84,075
of 359,669 outputs
Outputs of similar age from Journal of Neuro-Oncology
#5
of 55 outputs
Altmetric has tracked 22,772,779 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,964 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,669 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.